PLoS computational biology 2011-12-01

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

Zhichao Liu, Qiang Shi, Don Ding, Reagan Kelly, Hong Fang, Weida Tong

文献索引:J. Sci. Ind. Res. 65(10) , 808, (2006)

全文:HTML全文

摘要

Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI types (hepatotoxic side effects) seen in the clinic can be translated into the development of predictive in silico models for use in the drug discovery phase. We identified 13 hepatotoxic side effects with high accuracy for classifying marketed drugs for their DILI potential. We then developed in silico predictive models for each of these 13 side effects, which were further combined to construct a DILI prediction system (DILIps). The DILIps yielded 60-70% prediction accuracy for three independent validation sets. To enhance the confidence for identification of drugs that cause severe DILI in humans, the "Rule of Three" was developed in DILIps by using a consensus strategy based on 13 models. This gave high positive predictive value (91%) when applied to an external dataset containing 206 drugs from three independent literature datasets. Using the DILIps, we screened all the drugs in DrugBank and investigated their DILI potential in terms of protein targets and therapeutic categories through network modeling. We demonstrated that two therapeutic categories, anti-infectives for systemic use and musculoskeletal system drugs, were enriched for DILI, which is consistent with current knowledge. We also identified protein targets and pathways that are related to drugs that cause DILI by using pathway analysis and co-occurrence text mining. While marketed drugs were the focus of this study, the DILIps has a potential as an evaluation tool to screen and prioritize new drug candidates or chemicals, such as environmental chemicals, to avoid those that might cause liver toxicity. We expect that the methodology can be also applied to other drug safety endpoints, such as renal or cardiovascular toxicity.

相关化合物

结构式 名称/CAS号 全部文献
无水醋酸钠 结构式 无水醋酸钠
CAS:127-09-3
溴苯 结构式 溴苯
CAS:108-86-1
氢氯噻嗪 结构式 氢氯噻嗪
CAS:58-93-5
L-色氨酸 结构式 L-色氨酸
CAS:73-22-3
吡罗昔康 结构式 吡罗昔康
CAS:36322-90-4
氯化钠 结构式 氯化钠
CAS:7647-14-5
美芬妥因 结构式 美芬妥因
CAS:50-12-4
5-氨基水杨酸 结构式 5-氨基水杨酸
CAS:89-57-6
炔诺酮 结构式 炔诺酮
CAS:68-22-4
镁 结构式
CAS:7439-95-4